Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
AVIR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.75 - $4.15
Previous CloseN/A
Volume180.19K
Average Volume (3M)328.66K
Market Cap
$249.73M
Enterprise Value-$198.16M
Total Cash (Recent Filing)$64.70M
Total Debt (Recent Filing)$1.64M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 07, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding85,525,180
10 Day Avg. Volume339,291
30 Day Avg. Volume328,661
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.03
Forecast
1Y Price Target
$6.20Price Target Upside112.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Atea Pharmaceuticals News
PremiumCompany Announcements
Atea Pharmaceuticals’ Promising Earnings Call Highlights
PremiumCompany Announcements
Atea Pharmaceuticals Advances HCV Program with FDA Approval
PremiumCompany Announcements
Atea Pharmaceuticals Appoints Arthur Kirsch as Director
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of bemnifosbuvir and ruzasvir met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment in subjects with chronic hepatitis C infection.
Cost SavingsA workforce reduction by 25% is planned during the first quarter, which could lead to roughly $15 million in cost savings through 2027.
Bears Say
Financial PerformanceAtea reported a net loss of $33.5 million, or a loss of $0.40 per share.
---
Ownership Overview
11.72% Insiders
14.24% Mutual Funds
25.47% Other Institutional Investors
37.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVIR FAQ
What was Atea Pharmaceuticals’s price range in the past 12 months?
Atea Pharmaceuticals lowest stock price was $2.75 and its highest was $4.14 in the past 12 months.
What is Atea Pharmaceuticals’s market cap?
Atea Pharmaceuticals’s market cap is $249.73M.
When is Atea Pharmaceuticals’s upcoming earnings report date?
Atea Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 55 days.
How were Atea Pharmaceuticals’s earnings last quarter?
Atea Pharmaceuticals released its earnings results on Mar 06, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.289 by -$0.111.
Is Atea Pharmaceuticals overvalued?
According to Wall Street analysts Atea Pharmaceuticals’s price is currently Undervalued.
Does Atea Pharmaceuticals pay dividends?
Atea Pharmaceuticals does not currently pay dividends.
What is Atea Pharmaceuticals’s EPS estimate?
Atea Pharmaceuticals’s EPS estimate is -0.41.
How many shares outstanding does Atea Pharmaceuticals have?
Atea Pharmaceuticals has 85,525,180 shares outstanding.
What happened to Atea Pharmaceuticals’s price movement after its last earnings report?
Atea Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.289. Following the earnings report the stock price went down -0.333%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals?
Currently, no hedge funds are holding shares in AVIR
---
Atea Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.20 (112.33% Upside)
$6.20 (112.33% Upside)
Hedge Fund Trend
Decreased
By 90.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.54%
12-Months-Change
Fundamentals
Return on Equity
-33.88%
Trailing 12-Months
Asset Growth
-21.90%
Trailing 12-Months
Company Description
Atea Pharmaceuticals
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
---
AVIR Company Deck
---
AVIR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Atea Pharmaceuticals, driven by successful phase two trial results for the HCV program and a strong financial position. While there were challenges related to workforce reduction and cirrhotic patient recruitment, the company's strategic initiatives and financial health suggest a promising future.Read More>---
AVIR Stock 12 Month Forecast
Average Price Target
$6.20
▲(112.33% Upside)
Technical Analysis
Best Analysts Covering AVIR
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-2.30%
reiterated a buy rating 7 days ago
Copying Andy Hsieh's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -2.30% per trade.
---